EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Somedeb Ball, Farrukh T Awan iD, Ben K Tomlinson, Tess Stopczynski, Melissa A Fischer, Zhiguo Zhao, Kateryna Fedorov, Ashwin Kishtagari, Sanjay R Mohan, Gregory D Ayers, Michael T Byrne iD, Michael R Savona iD

American Journal of Hematology · 2026-05 · 101 (5) · 1019-1024

DOI: 10.1002/ajh.70266 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift American Journal of Hematology, online erschienen am 08.03.2026. Verfasst von Somedeb Ball und 11 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Hydrazines, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karyopharm Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) were enrolled. After the dose‐escalation phase, SEL 80 mg po weekly plus VEN 400 mg/day following ramp‐up was deemed the recommended phase II dose. Responses were assessed with IWG2003 and ELN 2022 criteria. Nineteen patients with R/R AML were enrolled. Median age at enrollment was 67.2 (range, 21.1–83.8) years. Overall, patients received median of 3 (range, 1–5) prior lines of therapy. The most common grade 3–5 treatment emergent adverse events (TEAE) were anemia (39%), neutropenia (33%), febrile neutropenia (28%), and thrombocytopenia (28%). Overall, the response rate with SEL‐VEN was 21%. Two (11%) patients, one with prior allo‐HSCT and one with prior VEN and both treated with SEL 80 mg/week, experienced complete remissions, with duration of response of 7 and 9.1 months, respectively. After a median follow up of 3.0 (range, 0.6–15.4) months, median event‐free survival was 2.4 (95% CI: 1.9–12.1) months and median overall survival was 6.4 (95% CI: 2.5–12.1) months. In conclusion, SEL‐VEN was feasible and active in a heavily pretreated AML cohort, with no new toxicity signal, but survival outcomes remained poor. The second‐generation XPO1‐inhibitor eltanexor, combined with VEN may further improve outcomes in VEN resistant AML in an ongoing study (NCT06399640).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrazinesLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsTriazolesHumansFemaleMiddle AgedAgedAdultMaleAged, 80 and overYoung AdultThrombocytopeniaRecurrenceDrug Resistance, Neoplasm

Substanzen

venetoclaxHydrazinesselinexorBridged Bicyclo Compounds, HeterocyclicSulfonamidesTriazoles

Autor:innen und Institutionen

  • Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.
  • Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Tennessee Oncology, Nashville, Tennessee, USA.

ORCID-Profile: Farrukh T Awan, Michael T Byrne, Michael R Savona

Förderung

  • Karyopharm Therapeutics

Zitieren

APA

Ball, S., Awan, F. T., Tomlinson, B. K., Stopczynski, T., Fischer, M. A., Zhao, Z., Fedorov, K., Kishtagari, A., Mohan, S. R., Ayers, G. D., Byrne, M. T., & Savona, M. R. (2026). Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia. American Journal of Hematology, 101(5), 1019-1024. https://doi.org/10.1002/ajh.70266

Vancouver

Ball S, Awan FT, Tomlinson BK, Stopczynski T, Fischer MA, Zhao Z, et al. Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia. American Journal of Hematology. 2026;101(5):1019-1024. doi:10.1002/ajh.70266

BibTeX
@article{Ball2026,
  author = {Ball, Somedeb and Awan, Farrukh T and Tomlinson, Ben K and Stopczynski, Tess and Fischer, Melissa A and Zhao, Zhiguo and Fedorov, Kateryna and Kishtagari, Ashwin and Mohan, Sanjay R and Ayers, Gregory D and Byrne, Michael T and Savona, Michael R},
  title = {Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {5},
  pages = {1019--1024},
  doi = {10.1002/ajh.70266}
}
Kostenlos starten →